Booth: 1

Through the merger of two major pharmaceutical companies with Japanese origin, completed in April 2007, Daiichi Sankyo strengthened its position as the number one pharmaceutical company by sales in Japan and as one of the 20 leading global pharmaceutical concerns. On the way to become a “Global Pharma Innovator”, the business mission is to focus on the company’s research activities to develop and commercialise innovative first and/or best in class products.

The current Daiichi Sankyo product range is focused on the treatment of cardiovascular diseases and diabetes.

Daiichi Sankyo Facts:

• Number one pharmaceutical company by sales in theJapanese market
• First company to develop a statin for hyperlipidaemia
• First company to develop a glitazone for diabetes
• 6,4 billion of worldwide net sales
• 17% global net sales invested in R&D
• One of the 20 leading global pharmaceutical companies
• 15,400 employees around the world
• 1,800 employees in Europe

Please come along to our symposium at ISN Nexus on Friday, November 30 from 12:45 to 13:15 to see how our innovative drugs are breaking new ground in hypertension and renal disease. We also hope that you will take a few minutes to visit our booth.

Booth: 2

AtCor Medical's SphygmoCor System can uniquely assess arterial stiffening - both local (PWV) and systemic - and then measure its impact at the heart on central blood pressures and on other key central heart function parameters. It is an important tool for assessing and managing the cardiovascular risk progression in your CKD patients. Visit our booth for a test and get new insight into YOUR cardiovascular risk profile